ArticlePloS one2026
Isolated superior rectus-levator complex enlargement: Inflammatory etiology, clinicoradiological features, and treatment outcomes.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo analyze the etiology, clinicoradiological features, and treatment outcomes of orbital inflammation presenting with isolated superior rectus-levator complex (SR-LC) enlargement.
methodsWe retrospectively reviewed patients treated for orbital inflammation with isolated SR-LC enlargement, assessing the underlying etiologies, including thyroid eye disease (TED), idiopathic orbital myositis (IOM), and immunoglobulin G4-related ophthalmic disease (IgG4-ROD). The IOM group was further divided by the presence of upper lid ptosis. Clinicoradiological findings and outcomes were compared between the TED and IOM groups.
resultsAmong the 58 patients, 39 (67.2%) had TED, 17 (29.3%) had IOM (10 without ptosis and seven with ptosis), and two (3.4%) had IgG4-ROD. Upper lid retraction was observed in both TED (79.5%) and IOM without ptosis (90.0%). SR tendon involvement was significantly less common in TED than in IOM (13.3% vs. 78.6%, p < 0.001). Infraduction limitation was more prevalent in TED (94.7%) and IOM with ptosis (100%) than in IOM without ptosis (25.0%), while supraduction limitation was noted in IOM without ptosis (75.0%). Compared to IOM without ptosis, IOM with ptosis had a shorter time to diagnosis (0.5 vs. 1.5 months, p = 0.088) and better clinical outcomes following steroid treatment (lid level asymmetry: 0% vs. 50.0%, p = 0.044).
conclusionTED and IOM are the most common etiologies of orbital inflammation with isolated SR-LC enlargement. IOM can manifest as either ptosis or retraction, with the latter distinguishable from TED by clinicoradiological features. Early initiation of systemic steroids can be associated with favorable clinical responses, especially for suspected IOM cases; however, further prospective studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.